TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10354716

Group type: EXPERIMENTAL
Intervention: Corticosteroids treatment in patients with idiopathic pulmonary fibrosis and avian fancier's lung
Number of subjects: 188

Group type: COMPARATOR
Intervention: Corticosteroids treatment in sarcoidosis patients
Number of subjects: 188

Group type: COMPARATOR
Intervention: No treatment in pulmonary fibrosis patients
Number of subjects: 188

Group type: COMPARATOR
Intervention: No treatment in sarcoidosis patients
Number of subjects: 188

Group type: COMPARATOR
Intervention: No treatment in avian fancier's lung patients
Number of subjects: 188
Study: 10499883

Group type: EXPERIMENTAL
Intervention: Repaglinide 1 mg before each meal
Number of subjects: 25

Group type: COMPARATOR
Intervention: Fixed-meal regimen
Number of subjects: 25

Group type: COMPARATOR
Intervention: Mixed-meal regimens
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 25
Study: 2374529

Group type: EXPERIMENTAL
Intervention: Cotrimoxazole for 21 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sequential therapy with cotrimoxazole followed by pentamidine inhalation for 21 days
Number of subjects: 12
Study: 668784

Group type: EXPERIMENTAL
Intervention: Oral chlordiazepoxide hydrochloride (50 mg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Intramuscular chlordiazepoxide hydrochloride (50 mg)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Oral chlordiazepoxide hydrochloride (100 mg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Intramuscular chlordiazepoxide hydrochloride (100 mg)
Number of subjects: 42
Study: 31982648

Group type: EXPERIMENTAL
Intervention: Machine learning-based prognostic algorithms and behavioral nudges to prompt oncologists to have serious illness conversations (SICs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 29771390

Group type: EXPERIMENTAL
Intervention: Smoke Free Intervention (SFI)
Number of subjects: 481

Group type: COMPARATOR
Intervention: Usual education (control)
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: SFI
Number of subjects: 481

Group type: COMPARATOR
Intervention: SFI vs Control
Number of subjects: 481
Study: 28825930

Group type: EXPERIMENTAL
Intervention: Mannequin-based simulation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Computer screen-based simulator
Number of subjects: 50
Study: 26510263

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 40
Study: 23308026

Group type: EXPERIMENTAL
Intervention: Explicit instructions to older siblings to supervise younger siblings and prevent specific risky behaviors
Number of subjects: 0

Group type: COMPARATOR
Intervention: No explicit instructions to older siblings
Number of subjects: 0
Study: 22105254

Group type: EXPERIMENTAL
Intervention: Oral misoprostol (75 micrograms)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Intravenous oxytocin
Number of subjects: 350
Study: 19199870

Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 63
Study: 16169654

Group type: EXPERIMENTAL
Intervention: Ethanol-based adhesive (Single Bond) on dry enamel
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ethanol-based adhesive (Single Bond) on wet enamel
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Acetone-based adhesive (Prime&Bond NT) on dry enamel
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Acetone-based adhesive (Prime&Bond NT) on wet enamel
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Self-etching adhesive (Clearfil SE Bond)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Acetone-based adhesives (in general)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ethanol-based adhesives (in general)
Number of subjects: 40
Study: 15351166

Group type: EXPERIMENTAL
Intervention: 0.05 mmol/kg body weight of Gd-DTPA
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: 0.10 mmol/kg body weight of Gd-DTPA
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: 0.15 mmol/kg body weight of Gd-DTPA
Number of subjects: 94
Study: 11524328

Group type: EXPERIMENTAL
Intervention: BIS monitoring
Number of subjects: 469

Group type: COMPARATOR
Intervention: Control (non-BIS monitoring)
Number of subjects: 469
Study: 9416950

Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enalapril (up to 40 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 0
Study: 8387087

Group type: EXPERIMENTAL
Intervention: Oral instructions indicating blood pressure would increase
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Oral instructions indicating blood pressure would decrease
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Oral instructions indicating no change in blood pressure
Number of subjects: 120

Group type: COMPARATOR
Intervention: No instructions (Control group)
Number of subjects: 120
Study: 3030946

Group type: EXPERIMENTAL
Intervention: Trimethoprim-polymyxin B sulfate cream
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fusidic acid cream
Number of subjects: 100
Study: 29102959

Group type: EXPERIMENTAL
Intervention: TRC101 (1.5, 3, or 4.5 g twice daily or 6 g once daily)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study: 27666887

Group type: EXPERIMENTAL
Intervention: Laparoscopic ultrasound guided group (n=57)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Laparoscopic group (n=54)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Open resection group (n=45)
Number of subjects: 156
Study: 24933221

Group type: EXPERIMENTAL
Intervention: Tongue Diagnosis System (TDS)
Number of subjects: 60
Study: 22243034

Group type: EXPERIMENTAL
Intervention: Specific acupoints of the stomach meridian (Group A)
Number of subjects: 712

Group type: COMPARATOR
Intervention: Sham acupuncture of non‐acupoints (Group E)
Number of subjects: 712

Group type: EXPERIMENTAL
Intervention: Other acupuncture groups (Group B, C, D)
Number of subjects: 712

Group type: EXPERIMENTAL
Intervention: Itopride (Group F)
Number of subjects: 712

Group type: EXPERIMENTAL
Intervention: All acupuncture groups
Number of subjects: 712

Group type: EXPERIMENTAL
Intervention: Group A vs other acupuncture groups
Number of subjects: 712
Study: 20805450

Group type: EXPERIMENTAL
Intervention: Multivitamin use during adjuvant chemotherapy
Number of subjects: 1038

Group type: EXPERIMENTAL
Intervention: Multivitamin use reported 6 months after completion of adjuvant chemotherapy
Number of subjects: 1038

Group type: EXPERIMENTAL
Intervention: Consistent multivitamin use during and following adjuvant therapy
Number of subjects: 1038

Group type: EXPERIMENTAL
Intervention: Increasing number of tablets or duration of use before cancer diagnosis
Number of subjects: 1038

Group type: EXPERIMENTAL
Intervention: Multivitamin use
Number of subjects: 1038
Study: 18575017

Group type: EXPERIMENTAL
Intervention: CPAP treatment for 3 days
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group C1 (mild or moderate SAS, not treated with CPAP)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group C2 (healthy subjects)
Number of subjects: 42
Study: 16203942

Group type: EXPERIMENTAL
Intervention: Lifestyle-focused, fitness-oriented gym classes (treatment group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard gym classes (control group)
Number of subjects: 50
Study: 11804987

Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 1134

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1134
Study: 10088935

Group type: EXPERIMENTAL
Intervention: Inhaled carbachol
Number of subjects: 166

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 166
Study: 7491818

Group type: EXPERIMENTAL
Intervention: Immunotherapy with Mycobacterium w vaccine
Number of subjects: 93

Group type: COMPARATOR
Intervention: MDT + placebo injections (Control)
Number of subjects: 93
Study: 2110437

Group type: EXPERIMENTAL
Intervention: Fleroxacin 200 mg for 10 days
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg for 10 days
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Fleroxacin 600 mg for 10 days
Number of subjects: 62
Study: 1147869

Group type: EXPERIMENTAL
Intervention: d-amphetamine (10 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: secobarbital (100 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo (no drug)
Number of subjects: 30
Study: 31600243

Group type: EXPERIMENTAL
Intervention: Oral B-12 2μg/day alone
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Oral B-12 2μg/day with multiple micronutrients (UNIMAPP formula + 20gm milk powder)
Number of subjects: 39
Study: 28470154

Group type: EXPERIMENTAL
Intervention: Strength based I‐change smoking cessation program
Number of subjects: 97

Group type: COMPARATOR
Intervention: General smoking cessation program
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group (no program)
Number of subjects: 97
Study: 25488587

Group type: EXPERIMENTAL
Intervention: BIAsp BID+Sit
Number of subjects: 582

Group type: EXPERIMENTAL
Intervention: BIAsp QD+Sit
Number of subjects: 582

Group type: COMPARATOR
Intervention: BIAsp BID
Number of subjects: 582
Study: 23752669

Group type: EXPERIMENTAL
Intervention: Low-energy diet (LED) (800‐1000 kcal/d) for 8 weeks followed by 8 weeks of reintroduction of normal food intake (1200 kcal/d)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low-energy diet (LED)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (ordinary healthy foods)
Number of subjects: 60
Study: 21921362

Group type: EXPERIMENTAL
Intervention: Vildagliptin (50 mg/day for 8 weeks, titrated to a maximum of 100 mg/day)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (no vildagliptin administered)
Number of subjects: 51
Study: 19555469

Group type: EXPERIMENTAL
Intervention: Plasma dehydroepiandrosterone sulfate (DHEAS)
Number of subjects: 1172

Group type: EXPERIMENTAL
Intervention: Total testosterone
Number of subjects: 1172

Group type: EXPERIMENTAL
Intervention: Calculated free testosterone
Number of subjects: 1172

Group type: EXPERIMENTAL
Intervention: Individual variants or haplotypes in AR, ESR2, PGR, CYP19 genes
Number of subjects: 1172

Group type: EXPERIMENTAL
Intervention: AR CAG repeat
Number of subjects: 1172
Study: 16449473

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Inositol
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 66
Study: 15290663

Group type: EXPERIMENTAL
Intervention: Mayo regimen
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: de Gramont regimen
Number of subjects: 150
Study: 11409513

Group type: EXPERIMENTAL
Intervention: Open ventriculoperitoneal (VP) shunt
Number of subjects: 54

Group type: COMPARATOR
Intervention: Conventional shunts
Number of subjects: 54
Study: 9210712

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy
Number of subjects: 0
Study: 8427432

Group type: EXPERIMENTAL
Intervention: Midazolam (1 mg/mL) administered until desired sedation achieved (max 5 mL)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Diazepam (2.5 mg/mL) administered until desired sedation achieved (max 5 mL)
Number of subjects: 69
Study: 3116290

Group type: EXPERIMENTAL
Intervention: Intravenous branched chain amino acid (BCAA) diet (60-80 g/day, BCAA content 51%, energy 2000 kcal/day)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nasogastric (NG) branched chain amino acid (BCAA) diet (amino acids 58 g, BCAA 43%, oligopeptides 19.5 g, energy 2000 kcal/day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Both groups (iv and NG)
Number of subjects: 8
Study: 29420152

Group type: EXPERIMENTAL
Intervention: Ischemic conditioning (IC)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 10
Study: 26782793

Group type: EXPERIMENTAL
Intervention: Rescue Board (RB)
Number of subjects: 35

Group type: COMPARATOR
Intervention: No Equipment (NE)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Fins
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Fins and Rescue Tube
Number of subjects: 35
Study: 25759404

Group type: EXPERIMENTAL
Intervention: Tianeptine (12.5 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24158142

Group type: EXPERIMENTAL
Intervention: Coloured zirconia cores with shade A2 and corresponding veneering ceramics (ICE Ceramic, GC Initial Zr, IPS e.max Ceram)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Non-coloured zirconia cores with corresponding veneering ceramics (ICE Ceramic, GC Initial Zr, IPS e.max Ceram)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control group (high noble alloys Esteticor Plus veneered with ceramic VM 13, n=16)
Number of subjects: 240
Study: 20870871

Group type: EXPERIMENTAL
Intervention: Double-balloon catheter with 3% polidocanol foam
Number of subjects: 20

Group type: COMPARATOR
Intervention: Follow-up at six months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Follow-up at twelve months
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Side effects reported
Number of subjects: 20
Study: 18266541

Group type: EXPERIMENTAL
Intervention: Mediation
Number of subjects: 109

Group type: COMPARATOR
Intervention: Litigation
Number of subjects: 109
Study: 16865041

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg MPH
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 15568935

Group type: EXPERIMENTAL
Intervention: Oxygenation-index images obtained from near-infrared imaging at wavelengths 690, 750, 788, and 856 nm.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Edge-corrected near-infrared optical mammograms.
Number of subjects: 0
Study: 11251616

Group type: EXPERIMENTAL
Intervention: Parenting intervention programme for adolescent mothers and their infants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (implied)
Number of subjects: 0
Study: 9418516

Group type: EXPERIMENTAL
Intervention: Behaviour modification techniques by professionals through eight home visits
Number of subjects: 0
Study: 8219559

Group type: EXPERIMENTAL
Intervention: Bypass surgery (BP)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty (PTA)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Overall (BP and PTA)
Number of subjects: 263
Study: 2890364

Group type: EXPERIMENTAL
Intervention: Tubocurarine 0.05 mg kg‐1
Number of subjects: 50

Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Vecuronium 0.012 mg kg‐1
Number of subjects: 50
Study: 31775831

Group type: EXPERIMENTAL
Intervention: Family intervention consisting of eight sessions of 90 min duration
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group receiving 2 h of psychoeducation
Number of subjects: 132
Study: 27436226

Group type: EXPERIMENTAL
Intervention: Self-expansion during treatment
Number of subjects: 239
Study: 26373711

Group type: EXPERIMENTAL
Intervention: Boston University approach to Psychiatric Rehabilitation (BPR)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Care As Usual (CAU)
Number of subjects: 225
Study: 24095984

Group type: EXPERIMENTAL
Intervention: 2.5% NaF/5% TMP
Number of subjects: 10

Group type: COMPARATOR
Intervention: 5% NaF
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (no F or TMP)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 2.5% NaF
Number of subjects: 10
Study: 22152238

Group type: EXPERIMENTAL
Intervention: TIPS combined with embolization of gastric coronary veins
Number of subjects: 122

Group type: COMPARATOR
Intervention: TIPS alone
Number of subjects: 122
Study: 19200379

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 17267927

Group type: EXPERIMENTAL
Intervention: 1.2 g eicosapentaenoic acid plus 0.9 g decosahexaenoic acid (n=22)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo (n=27)
Number of subjects: 49
Study: 15078794

Group type: EXPERIMENTAL
Intervention: ACHIEVE paclitaxel-coated stent
Number of subjects: 1043

Group type: COMPARATOR
Intervention: ML PENTA stent
Number of subjects: 1043
Study: 11332334

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 8-16 mg once daily
Number of subjects: 395

Group type: COMPARATOR
Intervention: Enalapril 10-20 mg once daily
Number of subjects: 395
Study: 9754981

Group type: EXPERIMENTAL
Intervention: Topical betaxolol (0.5%) administered 1-2 hours before surgery
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo administered 1-2 hours before surgery
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Topical betaxolol (0.5%) administered 48 hours before surgery
Number of subjects: 131
Study: 7871080

Group type: EXPERIMENTAL
Intervention: Caffeine placebo (C+)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Caffeine placebo (C-)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Alcohol placebo (A+)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Alcohol placebo (A-)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 50
Study: 3128139

Group type: EXPERIMENTAL
Intervention: Ro 15‐1788 at a dosage of 0.2 mg (2 ml)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 29223633

Group type: EXPERIMENTAL
Intervention: Postoperative irrigation with chlorhexidine for seven days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Postoperative chlorhexidine mouth rinse for seven days
Number of subjects: 100
Study: 27567361

Group type: EXPERIMENTAL
Intervention: IVF‐SET
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: IVF‐MNC
Number of subjects: 602

Group type: COMPARATOR
Intervention: IUI‐OS
Number of subjects: 602
Study: 24429540

Group type: EXPERIMENTAL
Intervention: Crystalline amino acid mixture with protein intakes of 0.1, 0.3, 0.6, 0.9, 1.2, 1.5, or 1.8 g · kg⁻¹ · d⁻¹
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Crystalline amino acid mixture
Number of subjects: 6
Study: 22633817

Group type: EXPERIMENTAL
Intervention: Dietary intervention group (IG) - instructed to reduce intake of insoluble dietary fibres and lactose
Number of subjects: 130

Group type: COMPARATOR
Intervention: Standard care group (SC) - instructed to continue normal diet
Number of subjects: 130
Study: 19889805

Group type: EXPERIMENTAL
Intervention: Iron-fortified rice (micronized ferric pyrophosphate)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Iron drops (control)
Number of subjects: 175
Study: 18477493

Group type: EXPERIMENTAL
Intervention: Mifepristone capsule (75 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Mifepristone tablet (75 mg)
Number of subjects: 18
Study: 15618262

Group type: EXPERIMENTAL
Intervention: CAST (Childhood Asperger Syndrome Test)
Number of subjects: 1925
Study: 12469154

Group type: COMPARATOR
Intervention: 24‐h protracted IV infusion of 5‐FU at 320 mg/m(2)/day for 5 days (CIV group)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 10‐min bolus IV infusion of 5‐FU at 320 mg/m(2)/day for 5 days (BIV group)
Number of subjects: 38
Study: 10915400

Group type: EXPERIMENTAL
Intervention: Clarithromycin suspension 7.5 mg/kg twice daily for 5 days
Number of subjects: 528

Group type: COMPARATOR
Intervention: Penicillin V suspension 13.3 mg/kg three times daily for 10 days
Number of subjects: 528
Study: 9012219

Group type: EXPERIMENTAL
Intervention: Innovative respiratory muscle training apparatus
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study: 1686562

Group type: EXPERIMENTAL
Intervention: GR122311X 196 mg b.d.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GR122311X 391 mg b.d.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GR122311X 782 mg b.d.
Number of subjects: 0

Group type: COMPARATOR
Intervention: 150 mg ranitidine b.d.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6662004

Group type: EXPERIMENTAL
Intervention: Indomethacin 0.5% solution eyedrops
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dexamethasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30714260

Group type: EXPERIMENTAL
Intervention: Pressure-controlled facemask ventilation at an inspiratory pressure of 13 cm H2O
Number of subjects: 151

Group type: COMPARATOR
Intervention: Manual facemask ventilation at an inspiratory pressure of 13 cm H2O
Number of subjects: 151
Study: 31158931

Group type: EXPERIMENTAL
Intervention: Normobaric oxygen (NBO2) therapy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO2) therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 40
Study: 27164985

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg for 3 days prior to surgery (including the day of surgery)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 24360571

Group type: COMPARATOR
Intervention: peginterferon α‐2a + RBV 800 mg/day (A; n=42)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: peginterferon α‐2a + RBV 1600 mg/day + epoetin β 400 IU/kg/week SC (B; n=55)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: peginterferon α‐2a + RBV 800 mg/day for a further 20 weeks (B1; n=42)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: peginterferon α‐2a + RBV 1600 mg/day + epoetin β (B2; n=13)
Number of subjects: 97
Study: 22586132

Group type: EXPERIMENTAL
Intervention: Moderate or heavy paternal alcohol consumption (at least weekly, ≥ 4 units per occasion)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transition into stepfamilies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stable single-parent families or transition into single-parent families
Number of subjects: 0
Study: 20461765

Group type: EXPERIMENTAL
Intervention: Gemcitabine 500 mg/m(2) IV weekly for 6 weeks with radiation to 50.4 Gy
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Gemcitabine 175 mg/m(2) on days 1, 5, 29, and 33, cisplatin 20 mg/m(2) on days 1‐5 and 29‐32, 5‐FU 600 mg/m(2) on days 1‐5 and 29‐32, followed by radiation with continuous infusion 5‐FU 225 mg/m(2) for 6 weeks
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Arm B (gemcitabine, cisplatin, 5-FU)
Number of subjects: 21
Study: 18789118

Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD) patients
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Continuous ambulatory peritoneal dialysis (CAPD) patients
Number of subjects: 58

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Patients with shoulder pain
Number of subjects: 58
Study: 16133138

Group type: EXPERIMENTAL
Intervention: Vitamin C with atypical antipsychotics
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo with atypical antipsychotics
Number of subjects: 40